Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B

Inclusion Criteria: HBsAg positive and anti-HBs negative for more than 6 months HBeAg positive HBV DNA titer more than 100,000 IU/mL serum ALT more than upper normal limit value, but no more than 10 times upper normal limit value Exclusion Criteria: the history of antiviral therapy for chronic hepatitis B within the recent 6 months HAV IgM Ab + and/or HCV Ab + and/or HDV Ab and/or HIV Ab + the sign of decompensated liver disease the history of hemoglobinopathy, autoimmune hepatitis, alcoholic liver disease pregnant or lactating woman neutrophil count less than 1,500/mm3 or platelet count less than 90,000/mm3 serum creatinine more than 1.5 times upper normal limit value the sign of alcoholic or drug addiction within the recent 1 year the history of psychotic disorder especially like depression immunologically mediated disease the history of esophageal varix the history of severe heart disease or respiratory disease the history of severe epilepsy or current use of antiepileptic drug the sign of malignancy or suggestive of malignancy or the history of malignancy, the recurrence rate within 2 years of which is more than 20% the history of systemic anticancer treatment including radiation therapy or immunotherapy including systemic corticosteroid the history of major organ transplantation the history of medically uncontrolled thyroid disease the history or sign of severe retinopathy